Drug Trial Radar · NCT05361382
Head-to-Head Harmonization of Tau Tracers in Alzheimer's Disease
Last checked: Nov 20, 2026Latest source record: Sep 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
822
Actual
Start
Mar 2, 2022
Primary completion
May 31, 2027
Study completion May 31, 2027
Sponsor
- Lead sponsor
- Tharick PascoalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- National Institute on Aging (NIA)
- First posted
- May 4, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Diagnostic
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 90 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to compare/harmonize cross-sectional and longitudinal tau tangle measurements obtained with the tau PET radiopharmaceuticals Flortaucipir and MK-6240 to elucidate the advantages and caveats of their use in clinical trials/practice and provide parameters to integrate their estimates.
Conditions
- Alzheimer Disease
Interventions
18F-Flortaucipir radiopharmaceuticalDrug
Flortaucipir is a PET radiopharmaceutical that binds to tau neurofibrillary tangles. Participants will receive a bolus intravenous injection of approximately 10 millicuries of the radiopharmaceutical.
18F-MK-6240 radiopharmaceuticalDrug
MK-6240 is a PET radiopharmaceutical that binds to tau neurofibrillary tangles. Participants will receive a bolus intravenous injection of approximately 5 millicuries of the radiopharmaceutical.
Amyloid-β radiopharmaceutical (11C-PiB or 18F-Florbetaben or 18F-NAV-4694 or 18F-Flutemetamol)Drug
The clinical sites will use either PiB, Florbetaben, Flutemetamol, or NAV-4694 as the amyloid-β PET radiopharmaceutical. The amyloid-β PET radiopharmaceutical binds to amyloid-β plaques. Participants will receive a bolus intravenous injection of approximately 15 millicuries of the PiB radiopharmaceutical. Participants will receive a bolus intravenous injection of approximately 8 millicuries of the Florbetaben or NAV-4694 radiopharmaceutical. Participants will receive a bolus intravenous injection of approximately 5 millicuries of the Flutemetamol radiopharmaceutical.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Cross-sectional tau PET uptake valuesTime frame: 2 years from enrollment
- Longitudinal change in tau PET uptake values over 18 monthsTime frame: 5 years from enrollment
Locations
9 sites in 3 countries. Site status is shown where the registry gives one.
Lawrence Berkeley National Laboratory
Berkeley, California
University of California San Francisco
San Francisco, California
Mayo Clinic
Rochester, Minnesota
Washington University in St. Louis
St Louis, Missouri
University of Pittsburgh
Pittsburgh, Pennsylvania
Brown University
Providence, Rhode Island
Houston Methodist Neurological Institute
Houston, Texas
McGill University
Montreal, Quebec, Canada
Sant Pau Biomedical Research Institute
Barcelona, Spain, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.